Hong Kong and Australia Biotech Groups Boost Cooperation
This article was originally published in PharmAsia News
The two groups hope member companies will benefit from Australia's expertise and Hong Kong's start-up scene.
You may also be interested in...
Lack Of Funding and Political Will Hinders Hong Kong’s Untapped Drug Discovery Research – ChinaBio Investor Forum
HONG KONG - Generally overshadowed by Singapore or Taiwan as a pharmaceutical and biotech center in Southeast Asia, Hong Kong has deep reserves of untapped knowledge and intellectual property
China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.
The Ministry of Health’s GSP regulation tries to plug a hole in supply chain security through tighter IT controls, such as requiring electronic barcodes.